Regarding the age determinant identified in the present study and in the GWTG-Stroke study, it is proposed that longer times may result from the weighting by both patient/family and physician of the benefits vs. risks of IV-tPA administration to older patients. The gene discussed is PLAT; the disease is Stroke.